These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Influence of infusion duration on the efficacy and toxicity of intravenous cyclosporine in bone marrow transplant patients. McGuire TR; Tallman MS; Yee GC; Nemunaitis JJ; Higano CS; McGuffin RW; Singer JW Transplant Proc; 1988 Jun; 20(3 Suppl 3):501-4. PubMed ID: 3291288 [No Abstract] [Full Text] [Related]
3. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Gluckman E; Devergie A; Lokiec F Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282 [No Abstract] [Full Text] [Related]
4. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012 [TBL] [Abstract][Full Text] [Related]
5. Cyclosporine administration practices on bone marrow transplant units: a national survey. Caudell KA; Adams J Oncol Nurs Forum; 1990; 17(4):563-8. PubMed ID: 2119035 [TBL] [Abstract][Full Text] [Related]
6. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants. Truog AW; Wozniak SP Oncol Nurs Forum; 1990; 17(1):39-44. PubMed ID: 2405360 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic studies of cyclosporine in bone marrow transplantation. Yee GC Transplant Proc; 1990 Jun; 22(3):1327-30. PubMed ID: 2190394 [No Abstract] [Full Text] [Related]
8. Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months. Yee GC; McGuire TR; St Pierre BA; Self SG; Zager RA; Sullivan KM; Deeg HJ Bone Marrow Transplant; 1989 Nov; 4(6):691-4. PubMed ID: 2684309 [TBL] [Abstract][Full Text] [Related]
9. Clinical correlations with cyclosporine blood levels after allogeneic bone marrow transplantation: an analysis of four different assays. Atkinson K; Downs K; Ashby M; Biggs J Transplant Proc; 1990 Jun; 22(3):1331-4. PubMed ID: 2190395 [No Abstract] [Full Text] [Related]
10. The correlation of cyclosporine serum and whole blood concentrations with toxicity and efficacy after human marrow transplantation. Britton K; Atkinson K; Downs K; Biggs J Transplant Proc; 1985 Apr; 17(2):1667-70. PubMed ID: 3885501 [No Abstract] [Full Text] [Related]
11. High resolution chromosomes for marrow transplant monitoring. Caimo A; Parodi C; De Filippi S; Rabitti C; Bacigalupo A; Rossi E Haematologica; 1986; 71(1):84-5. PubMed ID: 3084361 [No Abstract] [Full Text] [Related]
12. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. Storb R; Deeg HJ; Whitehead J; Farewell V; Appelbaum FR; Beatty P; Bensinger W; Buckner CD; Clift RA; Doney K Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942 [No Abstract] [Full Text] [Related]
13. Bone marrow transplantation for chronic myeloid leukemia. Speck B; Gratwohl A; Osterwalder B; Nissen C Semin Hematol; 1984 Jan; 21(1):48-52. PubMed ID: 6367057 [No Abstract] [Full Text] [Related]
14. Comparison of the safety and efficacy of oral vs constant-rate intravenous infusion cyclosporine immediately following orthotopic heart transplantation. Myre SA; Schroeder TJ; Melvin DB; Pesce AJ; Collins JA; Stephens GW; First MR Transplant Proc; 1989 Feb; 21(1 Pt 3):2484-6. PubMed ID: 2650310 [No Abstract] [Full Text] [Related]
15. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate. Tollemar J; Ringdén O; Heimdahl A; Lönnqvist B; Sundberg B Transplant Proc; 1988 Jun; 20(3 Suppl 3):470-9. PubMed ID: 3291283 [No Abstract] [Full Text] [Related]
16. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids. Ruutu T; Volin L; Elonen E Transplant Proc; 1988 Jun; 20(3):491-3. PubMed ID: 3289191 [No Abstract] [Full Text] [Related]
17. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease. Shepherd JD; Shore TB; Reece DE; Barnett MJ; Klingemann HG; Buskard NA; Phillips GL Bone Marrow Transplant; 1988 Nov; 3(6):553-8. PubMed ID: 3063323 [TBL] [Abstract][Full Text] [Related]
18. Prevention of graft versus host disease following allogeneic bone marrow transplantation. Powles RL; Goss GD; Millar J; Maitland J; Borthwick-Clark C; Al-Jundi A Tokai J Exp Clin Med; 1985 Jun; 10(2-3):133-8. PubMed ID: 3914738 [No Abstract] [Full Text] [Related]